Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says

MT Newswires Live07-14 02:56

Madrigal Pharmaceuticals (MDGL) announced three new patents for resmetirom earlier Monday, further strengthening its intellectual property portfolio and supporting the case for patent extension through 2045, Truist Securities said Monday.

The three new patents add to the patent covering weight-threshold dosing for resmetirom that was granted last year, providing potential protection into 2045, with competition from generics unlikely until then, according to the note.

While resmetirom is the only THR-beta agonist approved for metabolic dysfunction-associated steatohepatitis, Truist believes that any drug of the same mechanism of action would struggle to displace it due to these patents, the note added.

Truist said the third patent covering the treatment of well-compensated cirrhosis provides additional support for the next growth phase in advanced liver disease, as an expansion into F4 would nearly double the addressable market.

Truist kept its buy rating with a price target of $709.

Price: 533.16, Change: -3.54, Percent Change: -0.66

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651984149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 02:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651984149","market":"hk","top_or_hot":-1,"title":"Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says","media":"MT Newswires Live","content":"<html><body><p> Madrigal Pharmaceuticals (MDGL) announced three new patents for resmetirom earlier Monday, further strengthening its intellectual property portfolio and supporting the case for patent extension through 2045, Truist Securities said Monday.</p><p>The three new patents add to the patent covering weight-threshold dosing for resmetirom that was granted last year, providing potential protection into 2045, with competition from generics unlikely until then, according to the note.</p><p>While resmetirom is the only THR-beta agonist approved for metabolic dysfunction-associated steatohepatitis, Truist believes that any drug of the same mechanism of action would struggle to displace it due to these patents, the note added.</p><p>Truist said the third patent covering the treatment of well-compensated cirrhosis provides additional support for the next growth phase in advanced liver disease, as an expansion into F4 would nearly double the addressable market.</p><p>Truist kept its buy rating with a price target of $709.</p><p>Price: 533.16, Change: -3.54, Percent Change: -0.66</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMadrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-14 02:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Madrigal Pharmaceuticals (MDGL) announced three new patents for resmetirom earlier Monday, further strengthening its intellectual property portfolio and supporting the case for patent extension through 2045, Truist Securities said Monday.</p><p>The three new patents add to the patent covering weight-threshold dosing for resmetirom that was granted last year, providing potential protection into 2045, with competition from generics unlikely until then, according to the note.</p><p>While resmetirom is the only THR-beta agonist approved for metabolic dysfunction-associated steatohepatitis, Truist believes that any drug of the same mechanism of action would struggle to displace it due to these patents, the note added.</p><p>Truist said the third patent covering the treatment of well-compensated cirrhosis provides additional support for the next growth phase in advanced liver disease, as an expansion into F4 would nearly double the addressable market.</p><p>Truist kept its buy rating with a price target of $709.</p><p>Price: 533.16, Change: -3.54, Percent Change: -0.66</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651984149","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651984149","pubTimestamp":1783968990,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Madrigal Pharmaceuticals  announced three new patents for resmetirom earlier Monday, further strengthening its intellectual property portfolio and supporting the case for patent extension through 2045, Truist Securities said Monday.The three new patents add to the patent covering weight-threshold dosing for resmetirom that was granted last year, providing potential protection into 2045, with competition from generics unlikely until then, according to the note.While resmetirom is the only THR-beta agonist approved for metabolic dysfunction-associated steatohepatitis, Truist believes that any drug of the same mechanism of action would struggle to displace it due to these patents, the note added.Truist said the third patent covering the treatment of well-compensated cirrhosis provides additional support for the next growth phase in advanced liver disease, as an expansion into F4 would nearly double the addressable market.Truist kept its buy rating with a price target of $709.Price: 533.16","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","MDGL":"Madrigal Pharmaceuticals, Inc.","BK4588":"碎股","BK4139":"生物科技"},"translate_title":"Truist 表示，Madrigal Pharmaceuticals 的三项新专利支持专利延长至 2045 年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1.5},"content_text":"Madrigal Pharmaceuticals (MDGL) announced three new patents for resmetirom earlier Monday, further strengthening its intellectual property portfolio and supporting the case for patent extension through 2045, Truist Securities said Monday.The three new patents add to the patent covering weight-threshold dosing for resmetirom that was granted last year, providing potential protection into 2045, with competition from generics unlikely until then, according to the note.While resmetirom is the only THR-beta agonist approved for metabolic dysfunction-associated steatohepatitis, Truist believes that any drug of the same mechanism of action would struggle to displace it due to these patents, the note added.Truist said the third patent covering the treatment of well-compensated cirrhosis provides additional support for the next growth phase in advanced liver disease, as an expansion into F4 would nearly double the addressable market.Truist kept its buy rating with a price target of $709.Price: 533.16, Change: -3.54, Percent Change: -0.66","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651984149","isCrawlerRequest":true}